How do you think the launch of Onglyza will pan out in India?

Answers (1)

21 Apr 2012

The Launch of Onglyza will definitely hold a broad market in India. In India with around 51 Million diabetes patients.. India promises to be amongst the most lucrative diabetes markets in the world. In 2011 the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 448 Million. Although, this represents just a fraction of the global sales.

1) IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.
2) The total number of diabetes patients in India is expected to reach 87 Million by 2030.
3) Enhanced Medical Infrastructure – Numbers of doctors.
4) Treatment of Chronic disease.
5) Greater Health Insurance coverage.
6) New market in existing white space.


Votes: +0

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Similar questions

Does lafutidine really have a distinct advantage over H2RAs and PPIs? Is there any future for it?

this is to study the feasibility of a possible launch of Lafutidine in India

1 answer 6 May 2010

Which pharma company in india will launch tribenzor?

i need tribezor for analytical work.

2 answers 8 Sep 2010

Onglyza - has anyone experienced painful aches & pains in legs while taking onglyza.

I have Type 2 diabetes for about 3 years and I am currently on Amaryl twice a day. I have very high sugar readings in the morning. My doctor put me ...

6 answers 9 Mar 2011